SK Biopharmaceuticals Company Description

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders.

The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication.

It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder.

The company has collaborative research agreement with Korea Institute of Radiological and Medical Sciences for discovering and developing radiopharmaceutical drug candidates using an alpha-particle emitting radioisotope, actinium-225, for potential cancer treatments; and research collaboration agreement with ProEn Therapeutics for accelerating expansion of oncology research and pipeline for radiopharmaceuticals.

SK Biopharmaceuticals Co., Ltd. was founded in 1993 and is headquartered in Seongnam-si, South Korea.

SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.

SK Biopharmaceuticals Co., Ltd.

Country	South Korea
Founded	1993
Industry	Biotechnology
Sector	Healthcare
Employees	241
CEO	Dong Hoon Lee

Contact Details

Address: 221, Pangyoyeok-ro Seongnam-si, 13494 South Korea
Phone	82 31 8093 0114
Website	skbp.com

Stock Details

Ticker Symbol	326030
Exchange	Korea Stock Exchange
Fiscal Year	January - December
Reporting Currency	KRW
ISIN Number	KR7326030004
SIC Code	2834

Key Executives

Name	Position
Dong Hoon Lee	Chief Executive Officer, President and Executive Director
Jiyoung Jung	Chief Financial Officer and Executive Director